同步放化疗治疗Ⅲ期非小细胞肺癌的临床疗效及不良反应探讨

The clinical efficacy and adverse reactions of concurrent radiotherapy and chemotherapy in the treatment of stage Ⅲ non-small-cell lung cancer

目的探讨同步放化疗治疗Ⅲ期非小细胞肺癌患者的临床疗效,并观察其不良反应发生情况。方法68例Ⅲ期非小细胞肺癌患者,采用数字奇偶法分为同步组和序贯组,每组34例。序贯组采用序贯放化疗方法治疗,同步组采用同步放化疗方法治疗。对比两组患者临床疗效、不良反应发生情况、生存期限。结果同步组患者疾病总改善率85.29%(29/34)明显高于序贯组的58.82%(20/34),差异具有统计学意义(P<0.05)。同步组患者不良反应发生率26.47%(9/34)同序贯组的23.53%(8/34)比较差异无统计学意义(P>0.05)。同步组患者生存期限(20.29±2.29)个月明显长于序贯组的(11.13±2.13)个月,差异具有统计学意义(P<0.05)。结论同步放化疗治疗Ⅲ期非小细胞肺癌患者的改善效果显著,并且不会增加骨髓抑制、放射性食管炎、胃肠道反应、放射性肺炎等不良反应发生情况,显著延长患者生存期限,实现Ⅲ期非小细胞肺癌患者有效预后。

Objective To discuss the clinical efficacy of concurrent radiotherapy and chemotherapy in the treatment of stage Ⅲ non-small-cell lung cancer,and observe the occurrence of adverse reactions.Methods A total of 68 patients with stage Ⅲ non-small-cell lung cancer were divided into synchronous group and sequential group by digital parity method,with 34 cases in each group.The sequential group was treated with sequential radiotherapy and chemotherapy,and the synchronous group was treated with concurrent radiotherapy and chemotherapy.The clinical efficacy,occurrence of adverse reactions,and survival time of the two groups were compared.Results The total disease improvement rate 85.29%(29/34)of the synchronous group was significantly higher than 58.82%(20/34)of the sequential group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the synchronous group was 26.47%(9/34),which was not statistically significant compared with 23.53%(8/34)of the sequential group(P>0.05).The survival time(20.29±2.29)months of the synchronous group was significantly longer than(11.13±2.13)months of the sequential group,and the difference was statistically significant(P<0.05).Conclusion Concurrent radiotherapy and chemotherapy can significantly improve the effect of patients with stage Ⅲ non-small-cell lung cancer,and will not increase the incidence of adverse reactions such as bone marrow suppression,radiation esophagitis,gastrointestinal reaction and radiation pneumonia,significantly prolong the survival time of patients,and achieve the effective prognosis of patients with stage Ⅲ non-small-cell lung cancer.